| 标题 |
[高分]
149MO Irpagratinib (ABSK-011) plus atezolizumab in first-line (1L) and immune checkpoint inhibitors (ICIs) treated advanced hepatocellular carcinoma (HCC) with FGF19 overexpression (+): Updated results of the phase II ABSK-011-201 study |
| 网址 | |
| DOI | |
| 其它 |
期刊:Annals of Oncology 作者:Q. Cheng; Y. Zhang; J. Wang; L. Zhao; C. Hou; et al 出版日期:2025 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)